key: cord-0727884-81qxpyt8
authors: Çiftçiler, Rafiye; Haznedaroğlu, İbrahim C.
title: COVID-19, Renin-Angiotensin System, and Hematopoiesis
date: 2020-08-28
journal: Turk J Haematol
DOI: 10.4274/tjh.galenos.2020.2020.0174
sha: 75738f7456bc81ea8c62f7cf5e23778931145d0c
doc_id: 727884
cord_uid: 81qxpyt8

nan

Here we would like to point out that the hematopoietic effects of COVID-19/SARS viral infections including lymphopenia, leukoerythroblastosis, and macrophage activation syndrome may be linked to the viral effect on the local RAS [1] in the BM microenvironment. Leukoerythroblastic reactions associated with normocytic anemia, occasional nucleated red blood cells, mild anisocytosis, and rare dacrocytes were observed during the clinical course of COVID-19 infections [4] . Lymphopenia is a critical prognostic biomarker of the severity and hospitalization of the patients with COVID-19 [7] . The imbalance between the ACE/angiotensin II/AT1R pathway and ACE2/angiotensin (1-7)/Mas receptor pathway in the RAS leads to the multisystem inflammation [8] . Likewise, macrophage activation syndrome is an essential integral part of the COVID-19 pathophysiology [9] . Similarly, enhanced expression of ACE in the lymphoma-associated macrophages in the lymph nodes in Hodgkin's disease was previously demonstrated with regard to the local RAS [10] .

The interrelationship between COVID-19, RAS, and hematopoiesis is not just an academic concern since the future modulation of the local RAS may be performed with directed RAS modulators, such as soluble ACE2, angiotensin (1-7), TXA127, and MAS receptor agonists. Topical soluble ACE2 has already been suggested as a 'drug-of-hope' for the pharmacobiological management of COVID-19 based on future controlled clinical trials [11] . 

No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.

The authors declared that this study received no financial support.

Local bone marrow renin-angiotensin system in primitive, definitive and neoplastic haematopoiesis

The role of the local bone marrow renin-angiotensin system in multiple myeloma

Local reninangiotensin system in normal hematopoietic and multiple myeloma-related progenitor cells

Leukoerythroblastic reaction in a patient with COVID-19 infection

Hematological findings in SARS patients and possible mechanisms (review)

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study

Inhibitors of RAS might be a good choice for the therapy of COVID-19 pneumonia

COVID-19: Consider cytokine storm syndromes and immunosuppression

Angiotensin-converting enzyme expression of the lymphoma-associated macrophages in the lymph nodes of Hodgkin's disease

Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2

Immunosuppression in patients with hepatitis B virus (HBV) infection may result in viral reactivation. This risk is higher in patients with present than past HBV infection (hepatitis B surface antigen (HBsAg)-positive vs. HBsAg-negative, anti-HBc positive) and in patients with hematological malignancies and related treatments [1, 2] . Ibrutinib is a Bruton's tyrosine kinase inhibitor (TKI) indicated in the treatment of relapsed/ refractory chronic lymphocytic leukemia (CLL) [3] . The American Gastroenterological Association Institute categorized patients with past HBV infection treated with TKIs as having a moderate risk for HBV reactivation (HBVr) (1%-10%). There is only a weak recommendation for routine viral prophylaxis for HBVr in that guideline [2] , whereas in the ECIL-5 guideline, there is no suggestion about the management of these patients [4] . Here we describe a case of HBVr under ibrutinib monotherapy in a patient with past HBV infection and relapsed/refractory CLL. A 58-year-old man was diagnosed with CLL. His HBV serology was compatible with past infection (Figure 1 ). According to existing guidelines [1, 2] , follow-up of liver enzymes, HBV serology, and HBV-DNA every 3 months was planned without antiviral